Related references
Note: Only part of the references are listed.Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Qi Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas
Shenon Sethi et al.
FRONTIERS IN ONCOLOGY (2021)
Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL
Kallesh D. Jayappa et al.
BLOOD ADVANCES (2021)
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
Christian Winther Eskelund et al.
HEMASPHERE (2021)
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients
Preetesh Jain et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Shruti Bhatt et al.
CANCER CELL (2020)
BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
Xiaohong Zhao et al.
CANCER CELL (2019)
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Romain Guieze et al.
CANCER CELL (2019)
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Rishu Agarwal et al.
NATURE MEDICINE (2019)
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery et al.
CANCER DISCOVERY (2019)
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner
Konstantinos Dimopoulos et al.
MOLECULAR ONCOLOGY (2018)
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Lan V. Pham et al.
CLINICAL CANCER RESEARCH (2018)
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials
Rishu Agarwal et al.
LEUKEMIA & LYMPHOMA (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting BCL-2 in Hematologic Malignancies
Nadia Khan et al.
TARGETED ONCOLOGY (2018)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D. Herling et al.
NATURE COMMUNICATIONS (2018)
Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi
Jean-Philippe Fortin et al.
BIOINFORMATICS (2017)
BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma
Christelle Dousset et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Kallesh D. Jayappa et al.
BLOOD ADVANCES (2017)
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
Kamil Bojarczuk et al.
BLOOD (2016)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Christian W. Eskelund et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Identification of DNA Methylation-Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma
Elinne Becket et al.
CANCER RESEARCH (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip
Daniel L. McCartney et al.
GENOMICS DATA (2016)
Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes
Franziska Wilhelm et al.
GROWTH HORMONE & IGF RESEARCH (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
BH3 profiling in whole cells by fluorimeter or FACS
Jeremy Ryan et al.
METHODS (2013)
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Joshua E. Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
Jacqueline M. Tromp et al.
CLINICAL CANCER RESEARCH (2012)
IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription
Matei Mireuta et al.
GROWTH FACTORS (2010)
The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage
Peng Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Share Paper
